Imidazo[1,5-a][1,2,4]-triazolo[1,5-d][1,4]benzodiazepines as potent and highly selective GABAA α5 inverse agonists with potential for the treatment of cognitive dysfunction

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 20, 2009, Pages 5958-5961

  Buettelmann, Bernd ^a   Ballard, Theresa M ^a   Gasser, Rodolfo ^a   Fischer, Holger ^a   Hernandez, Maria Clemencia ^a   Knoflach, Frédéric ^a   Knust, Henner ^a   Stadler, Heinz ^a   Thomas, Andrew W ^a   Trube, Gerhard ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cognitive dysfunction; GABA A; Inverse agonism

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR BLOCKING AGENT; IMIDAZO[1,5 A][1,2,4]TRIAZOLO[1,5 D][1,4]BENZODIAZEPINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG METABOLISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; IN VIVO STUDY; MEMORY DISORDER; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ADJUVANTS, ANESTHESIA; ANIMALS; ANTICONVULSANTS; BENZODIAZEPINES; CELL LINE; COGNITION DISORDERS; DRUG INVERSE AGONISM; HUMANS; MEMORY, SHORT-TERM; MICROSOMES, LIVER; RATS; RECEPTORS, GABA-A; SCOPOLAMINE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 70349194485     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.08.027     Document Type: Article

References (17)

1. Bormann J. Trends Pharmacol. Sci. 21 (2000) 16
2. Simon J., Wakimoto H., Fujita N., Lalande M., and Barnard E.A. J. Biol. Chem. 279 (2004) 41422
3. McKernan R.M., and Whiting P.J. Trends Neurosci. 19 (1996) 139
4. Chouinard G. J. Clin. Pharmacol. 65 (2004) 7
5. Bentue-Ferrer D., Bureau M., Patat A., and Allain H. CNS Drug Rev. 2 (1996) 390
6. Dorow R., Horowski R., Paschelke G., Amin M., and Braestrup C. Lancet 2 (1983) 98
7. Dawson G.R., Maubach K.A., Collinson N., Cobain M., Everitt B.J., MacLeod A.M., Choudhury H.I., McDonald L.M., Pillai G., Rycroft W., Smith A.J., Sternfeld F., Tattersall F.D., Wafford K.A., Reynolds D.S., Seabrook G.R., and Atack J.R. J. Pharmacol. Exp. Ther. 316 (2006) 1335
8. Nutt D.J., Besson M., Wilson S.J., Dawson G.R., and Lingford-Hughes A.R. Neuropharmacology 53 (2007) 810
9. Chambers M.S., Atack J.R., Broughton H.B., Collinson N., Cook S., Dawson G.R., Hobbs S.C., Marshall G., Maubach K.A., Pillai G.V., Reeve A.J., and MacLeod A.M. J. Med. Chem. 46 (2003) 2227
10. Collinson N., Atack J.R., Laughton P., Dawson G.R., and Stephens D.N. Psychopharmacology 188 (2006) 619
11. Sternfeld F., Carling R.W., Jelley R.A., Ladduwahetty T., Merchant K.J., Moore K.W., Reeve A.J., Street L.J., O'Connor D., Sohal B., Atack J.R., Cook S., Seabrook G., Wafford K., Tattersall F.D., Collinson N., Dawson G.R., Castro J.L., and MacLeod A.M. J. Med. Chem. 47 (2004) 2176
12. We define compounds with an efficacy <-40% as 'full inverse agonists', compounds with an efficacy >-40% and <-25% as 'partial inverse agonists'and those with >-25% and <-10% as 'weak inverse agonists'.
13. Gerecke M., Kyburz E., Borer R., and Gassner W. Heterocycles 39 (1994) 693
14. Buettelmann, B.; Knust, H.; Thomas, A. U.S. Patent 2007082890; Chem. Abstr. 2007, 146, 422016.
15. Shishkov I.F., Khristenko L.V., Vilkov L.V., and Oberhammer H. J. Phys. Chem. A 108 (2004) 4966
16. Gonzalez R.C.B., Huwyler J., Boess F., Walter I., and Bittner B. Biopharm. Drug Dispos. 25 (2004) 37
17. Higgins G.A., Ballard T.M., Huwyler J., Kemp J.A., and Gill R. Neuropharmacology 44 (2003) 324